The combination of gemcitabine and oxaliplatin (GEM-OXAL) is feasible in patients with poor prognosis advanced non-small cell lung cancer (NSCLC). Results of a phase II study

Franciosi, Vittorio; Barbieri, Roberto; Vasini, G; Aitini, Enrico; Cacciani, C.; Capra, Riccardo; Greco, F. Anthony; Bozzetti, Cecilia; Cascinu, S.

doi:10.1016/s0959-8049(01)80692-4

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early results in 24 previously untreated (Hoffman et al, 2001), 28 previously untreated (Monnet et al, 2002) and 10 previously treated (Franciosi et al, 2001) patients show response rates of 25, 35 and 30%, respectively. Oxaliplatin monotherapy has also demonstrated activity in a small study of 33 patients with poor-prognosis NSCLC (Monnet et al, 1998).…”

Section: Regimens Containing Oxaliplatinmentioning

confidence: 98%

“…Three small studies are underway to assess combinations of oxaliplatin and gemcitabine (Franciosi et al, 2001), paclitaxel (Hoffman et al, 2001) or vinorelbine (Monnet et al, 2002) in patients with advanced NSCLC. Early results in 24 previously untreated (Hoffman et al, 2001), 28 previously untreated (Monnet et al, 2002) and 10 previously treated (Franciosi et al, 2001) patients show response rates of 25, 35 and 30%, respectively.…”

Section: Regimens Containing Oxaliplatinmentioning

confidence: 99%

See 1 more Smart Citation

Platinum drugs in the treatment of non-small-cell lung cancer

Cosaert

Quoix

2002

Br J Cancer

View full text Add to dashboard Cite

The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that cannot be treated with radiotherapy and in those with metastatic non-small-cell lung cancer and good performance status. This approach is also accepted in patients with earlier stage disease, when combined with radiotherapy in those with nonresectable locally advanced disease, or in the preoperative setting. Randomised clinical studies and meta-analyses of the literature have confirmed the beneficial survival effect of platinum-based chemotherapy. Cisplatin and carboplatin have been successfully used with other drugs in a wide variety of well-established two-drug combinations while three-drug combinations are still under investigation. Cisplatin and carboplatin use is limited by toxicity and inherent resistance. These considerations have prompted research into new platinum agents, such as the trinuclear platinum agent BBR3464, the platinum complex ZD0473 and oxaliplatin. These compounds could be developed in combination with agents such as paclitaxel, gemcitabine or vinorelbine in patients with advanced and/or refractory solid tumours.

show abstract

Section: Regimens Containing Oxaliplatinmentioning

confidence: 98%

Section: Regimens Containing Oxaliplatinmentioning

confidence: 99%

Platinum drugs in the treatment of non-small-cell lung cancer

Cosaert

Quoix

2002

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, there have been a number of favorable preliminary results in ovarian cancer patients reported in phase I-II studies [14][15][16][17] . The dose of choice of this experimental regimen was based on the results of clinical phase I-II dose finding studies that reported a recommended dose of 1000-1500 mg/m 2 for gemcitabine and 85-130 mg/m 2 for oxaliplatin [14][15][16][17][18] . Among these schedules we have chosen Louvet's regimen because of its low neurological toxicity profile 18 .…”

Section: Hematological and Nonhematological Toxicitymentioning

confidence: 99%

“…The overall response rate was 23%. The median duration of response was 5 months (range: [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19], while the median overall survival was 10 months…”

Section: Efficacy Datamentioning

confidence: 99%

Gemcitabine Combined with Oxaliplatin (GEMOX) as Salvage Treatment in Elderly Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum: a Single Institution Experience

Germano¹,

Rosati²,

Manzione³

2007

Journal of Chemotherapy

View full text Add to dashboard Cite

Both oxaliplatin (OXA) and gemcitabine (GEM) have shown single agent activity in patients with recurrent ovarian cancer. Response rates to second-line therapies remain low and there is a need to develop more effective regimens. In view of the synergistic effect of using GEM followed by OXA, we studied these agents in elderly patients with recurrent ovarian cancer refractory or resistant to first-line chemotherapy using platinum with or without paclitaxel. The aim of the study was to evaluate the efficacy and toxicity of combination GEM 1000 mg/m(2) Day 1 i.v. and OXA 100 mg/m(2) in 2h infusion Day 2; treatment was repeated every 2 weeks for 6 courses or until progression of disease or intolerable toxicity. The study was monoinstitutional and started in November 2002. 21 patients, median age 68.6 years (range 65-82) have been treated. Median Performance Status was 0-1, all had at least 1 prior platinum based chemotherapy and 11 had received also a taxane. Patients received a median of 6 cycles of treatment (range 4-11). There were 2 patient (9%) with complete response, 3 patients (14%) achieved a partial response. Low profile toxicity (grade 1-2, WHO criteria) was observed: nausea/vomiting 52%, thrombocytopenia 13%, neuropathy 28%. The GEMOX combination is well tolerated and even in this small group of patients, encouraging responses were documented.

show abstract

“…Furthermore, oxaliplatin in combination with irinotecan was incorporated in one of the sequential chemotherapy regimens based on the following factors: (1) Oxaliplatin has mechanism of action similar to that of other platinum derivatives, but its spectrum of anti-tumor activity against tumor model differs from those of cisplatin and carboplatin [10]. (2) It is an active agent in non-small cell lung cancer (NSCLC) and escapes the mechanisms of resistance of cisplatin mediated by the mismatch repair (MMR) mutation [11,12]. (3) Recent data has shown that deficiency in the mismatch repair system and increased ability of the replication complex to synthesize DNA past the site of DNA damage causes resistance to cisplatin but not to oxaliplatin [13].…”

Section: Introductionmentioning

confidence: 99%